Startups
Start Codon launched in Cambridge, England with funding from keystone investors including Cambridge Innovation Capital, Babraham Bioscience Technologies, Genentech, Jonathan Milner and Ian Tomlinson. Start Codon is a strategic initiative that’s targeting translating research into commercial companies.
The company focuses on developing drugs to treat chronic cough, although their technology may have broader implications for itch, pain and inflammation.
Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more.
Talaris, most recently known as Regenerex, will use the funding to launch a Phase III registration trial of its allogenic cell therapy in living donor kidney transplant recipients.
In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
The vast majority of immune cells are found in the gut but historically, the gut has been viewed as a liability to drug development. The question of whether or not greater understanding of harnessing the gut could drive more promising drug development has led to the formation of a new company, Kintai Therapeutics.
The $13.8 million facility that will include training sites, biotech wet laboratories, clean rooms, and office and event spaces is now looking for organizations and companies to fill the space.
Alexandria Real Estate Equities, which focuses on development of life science and technology campuses, launched its inaugural member class of seed- and early-stage life science companies at the Alexandria LaunchLabs – Cambridge.
Alcon CEO says the company is “poised to achieve sustainable growth and create long-term shareholder value as a standalone company.”
Life science incubators and accelerators play a highly significant role in the industry and may be the key for regional growth, a new report shows.
PRESS RELEASES